These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24607922)

  • 1. The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family.
    Ruotolo A; Di Taranto MD; D'Agostino MN; Marotta G; Gentile M; Nunziata M; Sodano M; Di Noto R; Del Vecchio L; Rubba P; Fortunato G
    Clin Chem Lab Med; 2014 Aug; 52(8):e175-8. PubMed ID: 24607922
    [No Abstract]   [Full Text] [Related]  

  • 2. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of genetic typing in human lipid disorders.
    Brown WV; Breslow J; Ballantyne C
    J Clin Lipidol; 2012; 6(3):199-207. PubMed ID: 22658144
    [No Abstract]   [Full Text] [Related]  

  • 8. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
    Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
    Levy E; Ben Djoudi Ouadda A; Spahis S; Sane AT; Garofalo C; Grenier É; Emonnot L; Yara S; Couture P; Beaulieu JF; Ménard D; Seidah NG; Elchebly M
    Atherosclerosis; 2013 Apr; 227(2):297-306. PubMed ID: 23422832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
    Saavedra YG; Zhang J; Seidah NG
    PLoS One; 2013; 8(8):e72113. PubMed ID: 23951290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form.
    Rocha CS; Wiklander OP; Larsson L; Moreno PM; Parini P; Lundin KE; Smith CI
    J Mol Cell Cardiol; 2015 May; 82():186-93. PubMed ID: 25791168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM; Yamamoto L; Shelton DL; Liang H
    PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proprotein convertases and their implication in sterol and/or lipid metabolism.
    Seidah NG; Khatib AM; Prat A
    Biol Chem; 2006 Jul; 387(7):871-7. PubMed ID: 16913836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
    Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
    Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro.
    Schroeder CI; Swedberg JE; Withka JM; Rosengren KJ; Akcan M; Clayton DJ; Daly NL; Cheneval O; Borzilleri KA; Griffor M; Stock I; Colless B; Walsh P; Sunderland P; Reyes A; Dullea R; Ammirati M; Liu S; McClure KF; Tu M; Bhattacharya SK; Liras S; Price DA; Craik DJ
    Chem Biol; 2014 Feb; 21(2):284-94. PubMed ID: 24440079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
    Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
    Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.